Learning Objectives

  • Demonstrate an increase in your knowledge of clinical medicine.
  • Evaluate the appropriateness of clinical information as it applies to the care of your patients.
  • Demonstrate an improvement in your ability to make decisions that provide safe and effective medical care.
  • Recognize areas of personal strength and areas for growth in clinical knowledge.

Intended Audience

Physician assistants and physician assistant students who are seeking to maintain and augment their knowledge and/or who are preparing for their initial board certification or recertification.

AAPA Self-Assessment CME Credit

AAPA Category 1 Self-Assessment CMEThis activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 225 AAPA Category 1 Self-Assessment CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 6/1/2023 to 6/1/2024. AAPA reference number: 209296.

For NCCPA certification maintenance ONLY: NCCPA will now apply an additional 50 percent weighting when these self-assessment credits are logged for NCCPA certification maintenance purposes. PAs should log up to a maximum of 225 AAPA Category 1 Self-Assessment CME credits, as the additional weighting will be automatically applied by NCCPA.

You will receive one credit for every ten questions you answer correctly.

CME Disclosure

All persons who may impact the content of a CME activity, including faculty and planners, are required to fully disclose current and recent financial relationships with commercial interests. A conflict of interest may be considered to exist if such a person has financial relationships with the grantor or any non-eligible entities (commercial interests) that may have a direct impact on the content of the program. Financial relationship is defined as being a shareholder, consultant, grant recipient, research participant, employee, and/or recipient of other financial or material support. Recent is defined as within the past 24 months.

MMS Disclosure Policy

The Massachusetts Medical Society (MMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and must ensure independence, balance, and scientific rigor in its accredited continuing education activities.

All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies for the previous 24 months.

Individual Disclosures

Below are all relevant financial relationships reported by NEJM Knowledge+ contributors during the past 3 years.

Vaneeta Bamba, MD
2022Nothing disclosed
2023Nothing disclosed
2024Novo Nordisk, Scientific Advisory Board on Long-Acting Growth Hormone, discontinued Oct 2023
  Ethan Brown, MD
2022Rune Labs, consultant
2023Nothing disclosed
  Steven Chen, MD
2022Pfizer, advisory board member, discontinued May 2021
Novartis, advisory board member, discontinued Dec 2021
2024Pfizer, advisory board member, discontinued Mar 2023
Scholar Rock, consultant, discontinued Sep 2022
Argenx, advisory board member, discontinued Nov 2022
  Ezra M. Cohen, MD
2022Nothing disclosed
2023Presidio, scientific board member
2024Nothing disclosed
  Nathan Connell, MD
2022Takeda Pharmaceutical, consultant
2023Takeda Pharmaceutical, consultant
Octapharma, honoraria
Genentech, advisory board member
Doximity, equity
2024Takeda Pharmaceutical, consultant and advisory board member
Octapharma, honoraria
Sanofi, advisory board member
Pfizer, honoraria
Bayer, advisory board member
Doximity, equity
  Glenn J. Hanna, MD
2022Actuate Therapeutics, grant/funding
Bicara, consultant/advisory board
Bicara, grant/funding
Boxer Capital, consultant
Bristol Myers Squibb, grant/funding
Bristol Myers Squibb, consultant
Coherus, consultant
Elevar, consultant/advisory board
Exicure, grant/funding, discontinued Jan 2022
Exicure, consultant/advisory board
Gateway for Cancer Research, grant/funding
Genentech, grant/funding
General Catalyst, consultant
GlaxoSmithKline, grant/funding
ImmunityBio, grant/funding
Kartos Therapeutics, grant/funding
Kite Pharma, grant/funding, discontinued Jun 2022
KSQ Therapeutics, consultant
KSQ Therapeutics, grant/funding
Kura Oncology, consultant/advisory board
Kura Oncology, grant/funding
Merck, consultant/advisory board
Naveris, consultant/advisory board
Prelude, consultant/advisory board
Rain Therapeutics, consultant, discontinued Nov 2021
Regeneron, consultant/advisory board
Regeneron, grant/funding
Remix Therapeutics, consultant/advisory board
Repertoire, grant/funding
Sanofi Genzyme, advisory board, discontinued Nov 2021
Sanofi Genzyme, grant/funding
Secura Bio, grant/funding
V Foundation, grant/funding, discontinued Jun 2022
2024ACCRF, grant/funding
Actuate Therapeutics, grant/funding
ASCO Conquer Cancer Foundation, grant/funding
Bicara, grant/funding
Bicara, consulting/advisory boards and honoraria
Bristol-Myers Squibb, grant/funding
Boxer Capital, consulting/advisory boards and honoraria, discontinued Jun 2023
Coherus, consulting/advisory boards and honoraria
Elevar, grant/funding
Elevar, consulting/advisory boards and honoraria, discontinued Nov 2022
Exicure, grant/funding
Gateway for Cancer Research, grant/funding
Genentech, grant/funding
GlaxoSmithKline, grant/funding
Grey Wolf Therapeutics, consulting/advisory boards and honoraria, discontinued Feb 2024
Guardian Bio, consulting/advisory boards and honoraria, discontinued Apr 2023
ImmunityBio, grant/funding
Inhibrx, consulting/advisory boards and honoraria
Kartos Therapeutics, grant/funding
Kite Pharma, grant/funding
KSQ Therapeutics, grant/funding
KSQ Therapeutics, consulting/advisory boards and honoraria, discontinued Nov 2022
Kura Oncology, grant/funding
Kura Oncology, consulting/advisory boards and honoraria
Merck, consulting/advisory boards and honoraria
Naveris, consulting/advisory boards and honoraria
Nextech, consulting/advisory boards and honoraria, discontinued May 2023
PDS Biotech, consulting/advisory boards and honoraria, discontinued Oct 2023
Regeneron, grant/funding
Regeneron, consulting/advisory boards and honoraria
Remix, consulting/advisory boards and honoraria, discontinued Apr 2023
Repertoire, grant/funding
Replimune, consulting/advisory boards and honoraria
Sanofi Genzyme, grant/funding
Secura Bio, grant/funding
Surface Oncology, consulting/advisory boards and honoraria, discontinued May 2023
V Foundation, grant/funding
  Jonathan S. Hausmann, MD
2022Pfizer, consultant, discontinued Dec 2020
Biogen, consultant, discontinued Dec 2020
Novartis, consultant
2023Fresenius Kabi, consultant
Novartis, consultant
2024Novartis, consultant
  Brian C. Healy, MD
2022Analysis Group, research support to institution, discontinued Nov 2020
Celgene (Bristol Myers Squibb), research support to institution, discontinued Nov 2020
Novartis, research support
2023Novartis, research support
2024Novartis, research support
  Koyal Jain, MD, MPH
2022PI for Kaneka study and Visterra study
  Mihir M. Kamdar, MD
2022Nothing disclosed
2023Elevate, cofounder and chief medical officer Fern Health, medical advisor
  Ruslan Korets, MD
2022Boston Scientific, consultant
2023Boston Scientific, consultant
2024Boston Scientific, consultant
Olympus, consultant
  Lekha M. Rao, MD
2023Epigenyx Therapeutics, consultant
UCB, principal investigator for a clinical trial
Eisai, principal investigator for a clinical trial
2024Epigenyx Therapeutics, consultant
  Leigh C. Reardon, MD
2022Janssen, advisory committee
2023Janssen, consultant
2024Nothing disclosed
  Eric Roeland, MD
2023Napo Pharmaceuticals, scientific advisory board
Actimed Therapeutics, scientific advisory board
Meter Health, scientific advisory board
Veloxis Pharmaceuticals, consultant
Aileron Therapeutics, consultant
BYOMass, consultant
Takeda, advisory board
Enzychem Lifesciences Pharmaceutical Company, data safety monitoring board
2024Actimed Therapeutics, scientific advisory board
Takeda, scientific advisory board, discontinued Apr 2022
Napo Pharmaceuticals, scientific advisory board
Meter Health, scientific advisory board, discontinued May 2022
Pfizer, speaker, discontinued Sep 2023
Dexcel Pharma, consultant, discontinued Sep 2023
  Deborah R. Stein, MD
2022Nothing disclosed
2023Horizon, consultant Alexion, consultant
2024Nothing disclosed
  Mitchell Strominger, MD
2022Nothing disclosed
2023Nothing disclosed
2024Amgen, speakers bureau and advisory board member, discontinued Mar 2024
  Joji Suzuki, MD
2023Indivior, research support, discontinued Aug 2023
  Raymond Y. Wang, MD
2022Biomarin, ad hoc advisory board, discontinued Oct 2021
Orphazyme, ad hoc FDA advisory meeting, discontinued Oct 2021
Sio Gene Therapies, consultant, discontinued Nov 2021
Sio Gene Therapies, ad hoc advisory board, discontinued Aug 2021
Inventiva Pharmaceutical, ad hoc advisory board, discontinued Jul 2021
Takeda Pharmaceutical, ad hoc advisory board, discontinued Mar 2021
Ultragenyx, speaker, discontinued Nov 2020
Neurogene, ad hoc advisory board, discontinued Oct 2020
Regenxbio, ad hoc advisory board, discontinued Apr 2020
2023RegenxBio, consultant
Takeda Pharmaceutical, advisory committee, discontinued 2022
Denali, drug safety monitoring board
2024Takeda Pharmaceutical, advisory committee, discontinued Feb 2023
REGENXBIO, speaker, discontinued Feb 2023
M6P Therapeutics, advisory board member
  Sharmeel K. Wasan, MD
2022Nothing disclosed
2023Nothing disclosed
2024Nothing disclosed

All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. All other individuals in control of the content have reported no relevant financial relationships with ineligible companies for this activity. The complete list of contributors can be found here.

Disclosure of Commercial Support

No commercial support was received for this activity.

Medium or Combination of Media Used

This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.

Estimated Time to Complete the Educational Activity

One hour for every 10 questions answered correctly.

Bibliography

Each clinical vignette includes citations and references.

Hardware/Software Requirements

Browsers

In general, we support the two latest versions of major browsers:

  • Edge (Recommended for best performance)
  • Chrome (Recommended for best performance)
  • Firefox
  • Safari

Systems Minimum Requirements

  • Screen Size: 4.5″+ (mobile)
  • Some content types might not work on small screens
  • Win10+ with 4GB+ RAM (8GB+ recommended)
  • macOS 11+ with 4GB+ RAM (6GB+ recommended
  • Android 10+ with 2GB+ RAM
  • iOS 12+ with 2GB+ RAM (Devices from 2019+ recommended)
  • Internet bandwidth: 1Mbit/s+ bandwidth (10MBit/s recommended, depends on content type)

Contact Information

For all questions and comments, please contact NEJM Knowledge+ by email at knowledgeplussupport@nejm.org or call toll-free +1-855-318-9303 (within the USA and Canada) or +1-781-434-7998.

Policy on Privacy and Confidentiality

Read our Privacy Policy.

Copyright

Copyright information can be found in the NEJM Group Terms of Use.